Sanofi and Teva had already shown in late 2024 that the anti-TL1A antibody, called duvakitug, improved outcomes in ulcerative ...

NImmune Biopharma ("NImmune"), a private late-stage precision inflammation and immunology ("I&I") biopharmaceutical company, today announced that Executive Chairman, President and CEO Dr. Josep ...

Teva Pharmaceutical Industries Limited TEVA shares are higher during Tuesday’s premarket session as the company is discussing ...

A new study suggests that combining routine stool tests and tracking habitual dietary patterns could help to predict IBD ...

Appointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn’s disease; Phase 2 ulcerative colitis IND submission planned for first half of 2026 ...

Patients with inflammatory bowel disease and precancerous colorectal lesions face an increased risk of developing colorectal cancer, with risk levels tied to the severity of the lesions, according to ...

Sanofi and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s ...

"Our results indicate that [the presence of micro- and nanoplastics] is a previously underestimated factor in the development ...

People with inflammatory bowel disease (IBD) and precancerous colorectal lesions are much more likely to develop colorectal cancer, a new study shows. Led by researchers from NYU Langone Health, the ...

Inflammatory bowel disease (IBD) is an umbrella term for a group of chronic conditions that cause inflammation and swelling ...

Inflammatory bowel disease (IBD) is typically diagnosed after the onset of symptoms in the context of established, characteristic patterns of intestinal inflammation. However, there is now substantial ...